Eli Lilly (LLY)
(Delayed Data from NYSE)
$952.74 USD
-1.43 (-0.15%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $950.50 -2.24 (-0.24%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$952.74 USD
-1.43 (-0.15%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $950.50 -2.24 (-0.24%) 7:58 PM ET
2-Buy of 5 2
D Value F Growth B Momentum F VGM
Zacks News
5 ETFs to Make the Most of Eli Lilly's Strength
by Sweta Killa
Impressed by Eli Lilly's (LLY) blowout earnings, several analysts raised their target price on the stock.
International Markets and Lilly (LLY): A Deep Dive for Investors
by Zacks Equity Research
Review Lilly's (LLY) international revenue performance and how it affects the predictions of financial analysts on Wall Street and the future prospects for the stock.
Nektar's (NKTR) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Nektar (NKTR) reports a wider-than-expected loss in the second quarter of 2024 while revenues beat estimates. Stock falls in after-hours trading.
Pharma Stock Roundup: LLY, NVO, BAYRY Q2 Earnings, MRK's New Deal & Other Updates
by Kinjel Shah
Eli Lilly (LLY), Novo Nordisk (NVO) and Bayer (BAYRY) announce second-quarter results. Merck (MRK) expands existing co-development deal with partner Daiichi Sankyo.
Company News for Aug 9, 2024
by Zacks Equity Research
Companies in The News Are: CYBR, PH, LLY, DDOG
Twilio and Floor & Decor Holdings have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Twilio and Floor & Decor Holdings have been highlighted as Zacks Bull and Bear of the Day
Eli Lilly: The Next $1 Trillion Market Cap Stock?
by Ethan Feller
Eli Lilly showcased the exceptional strength of its business during its quarterly earnings meeting on Thursday morning
Eli Lilly (LLY) Q2 Earnings Top, Mounjaro, Zepbound Drive View
by Zacks Equity Research
Eli Lilly (LLY) beats second-quarter estimates for earnings and sales. It raises its guidance for 2024 on strong demand for Mounjaro and Zepbound.
Continuing Claims Hit Highest Since Nov 2021
by Zacks Equity Research
Continuing Claims Hit Highest Since Nov 2021
Jobless Claims Decline, Pre-Markets in the Green
by Zacks Equity Research
It???s a big day for Wall Street as the much-awaited Jobless Claims numbers are out, which could be a major factor in market moves for the rest of the week.
Compared to Estimates, Lilly (LLY) Q2 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Lilly (LLY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Eli Lilly (LLY) Surpasses Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Lilly (LLY) delivered earnings and revenue surprises of 48.48% and 14.99%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Amgen (AMGN) Stock Down Despite Q2 Earnings & Sales Beat
by Zacks Equity Research
Amgen (AMGN) beats second-quarter 2024 estimates for earnings and sales. It tightens its revenue and earnings guidance range for 2024. Stock falls.
Eli Lilly (LLY) & Novo Nordisk (NVO) Earnings: A Closer Look
by Derek Lewis
Given their underperformance in 2024, a positive set of quarterly results could easily push both stocks higher.
Can Mounjaro & Zepbound Drive Eli Lilly (LLY) Q2 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.
Will These 5 Medical Stocks Surpass Q2 Earnings Forecasts?
by Kanishka Das
Let's look at five biotech and drug companies, AMGN, GILD, LLY, VTRS & NVO, due to release their second-quarter 2024 results this week.
Should You Buy, Sell or Hold Lilly (LLY) Ahead of Q2 Earnings?
by Kinjel Shah
Investor focus is likely to be on the sales numbers of Lilly's (LLY) tirzepatide medicines Mounjaro and Zepbound.
Lilly (LLY) Q2 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Lilly (LLY), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2024.
Company News for Aug 2, 2024
by Zacks Equity Research
Companies In The Article Are: LLY,MGM,SO and TRP
Eli Lilly (LLY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here is What to Know Beyond Why Eli Lilly and Company (LLY) is a Trending Stock
by Zacks Equity Research
Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
by Zacks Equity Research
Sector ETF report for XLV
Is First Trust Health Care AlphaDEX ETF (FXH) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for FXH
Incyte's (INCY) Q2 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Incyte's (INCY) second-quarter 2024 earnings miss estimates while revenues beat the same. The company raises the bottom end of the 2024 revenue guidance for its lead drug, Jakafi.
Merck (MRK) Q2 Earnings and Revenues Top Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 5.56% and 1.35%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?